To evaluate the efficacy and safety of KP-496NS for patients with perennial allergic rhinitis

To evaluate the efficacy and safety of KP-496NS for patients with perennial allergic rhinitis - An exploratory study of KP-496NS (Phase II)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001809

Enrollment

150

Registered

2009-04-01

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perennial allergic rhinitis

Interventions

Placebo KP-496NS 0.1% KP-496NS 0.3%

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients having moderate or severe perennial allergic rhinitis and nasal songestion (2) Patients giving a written informed consent (3) Patients having tested positive for both of the following allergic tests 1) Specific IgE radio-allergo-sorbent-test (RAST) 2) Nasal eosinophil count

Exclusion criteria

Exclusion criteria: (1) Patients having diseases that could interfere with assessment of treatment (2) Patients are/having recieved treatment for diseases that could interfere with assessment of treatment (3) Patients with bleeding tendency (4) Patients with problems in safety

Design outcomes

Primary

Measure	Time frame
Nasal symptom score, rhinoscopic findings, side effects	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026